AI-Guided Discovery of Small Molecule LILRB4 (ILT3) Inhibitors Reprograms Microglia and Reduces Amyloid Pathology
Abdel-Rahman, S.; Gabr, M.
Show abstract
The inhibitory microglial receptor LILRB4 (ILT3) suppresses amyloid-beta clearance in Alzheimers disease (AD) through ApoE-dependent signaling but remains undrugged by small molecules. Here, we report the AI-guided discovery of small molecule inhibitors that directly disrupt the LILRB4-ApoE interaction. Ultralarge-scale screening of [~]500 million compounds identified small molecules that bind LILRB4 with nanomolar affinity and competitively block ApoE engagement, as validated across orthogonal biophysical assays. Structural and mutational analyses define a tractable interdomain pocket that mediates ligand recognition. In human iPSC-derived microglia, LILRB4 inhibition suppresses SHP1/2-dependent signaling, attenuates NF-{kappa}B activation, and restores A{beta} uptake. The lead compound exhibits favorable pharmacokinetics with robust brain penetration and, upon oral administration, improves cognitive performance, reduces amyloid burden, and dampens neuroinflammation in the 5xFAD mouse model. These findings establish LILRB4 as a druggable neuroimmune checkpoint and demonstrate that small molecule disruption of inhibitory microglial signaling can restore disease-relevant function in vivo.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease 95%
- Discovery of CD28-Targeted Small Molecule Inhibitors of T Cell Co-stimulation Using Affinity Selection-Mass Spectrometry (AS-MS) and Ex Vivo Validation 95%
- Optimization and Characterization of SHIP1 Ligands for Cellular Target Engagement and Activity in Alzheimer's Disease Models 95%
Similar papers in this journal
- Development of a First-in-Class RIPK1 Degrader to Enhance Antitumor Immunity 95%
- Enhancing Intracellular Accumulation and Target Engagement of PROTACs with Reversible Covalent Chemistry 95%
- The Endo-GeneScreen Platform Identifies Drug-Like Probes that Regulate Endogenous Protein Levels within Physiological Contexts 95%
Similar papers in this journal
- Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer 94%
- Iterative computational design and crystallographic screening identifies potent inhibitors targeting the Nsp3 Macrodomain of SARS-CoV-2 94%
- PTP1B inhibition promotes microglial phagocytosis in Alzheimer's disease models by enhancing SYK signaling 94%
Similar papers in this journal
- A direct high-throughput protein quantification strategy facilitates discovery and characterization of a celastrol-derived BRD4 degrader 94%
- Structure-aided development of small molecule inhibitors of ENPP1, the extracellular phosphodiesterase of the immunotransmitter cGAMP 94%
- Targeting the PI5P4K lipid kinase family in cancer using novel covalent inhibitors 94%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.